A New Decade of ME Research: The 11th Invest in ME International ME Conference 2016
Mark Berry presents the first in a series of articles on the 11th Invest in ME International ME Conference in London ...
Discuss the article on the Forums.

Rituximab Phase III - Negative result

Discussion in 'Latest ME/CFS Research' started by Marky90, Nov 21, 2017.

  1. FMMM1

    FMMM1

    Messages:
    91
    Likes:
    147
    Thanks for your reply; I had a look at article. Here's hoping they come up with something.

    The United Kingdoms leaving the European Union so a possible source of science funding may not be available (EU Horizon 2020); it will be interesting to see whether the EU starts/increases funding ME/CFS research.
     
    MEMum likes this.
  2. FMMM1

    FMMM1

    Messages:
    91
    Likes:
    147
    Couldn't agree more but keep an eye out for Maureen Hanson's collaborative study (with a Norwegian group) on probiotics it's due to end this year i.e. 2017 (check out Hanson's talk at the symposium for details) .

    I think the science is complicated and presumably the more important question is how do we get it funded (and fast)?
     
    anni66 likes this.
  3. FMMM1

    FMMM1

    Messages:
    91
    Likes:
    147
    Thank you for this I hadn't realised there was a 2016 paper dealing with "changes in kidney's handling of electrolytes". This is also in one of the slides (12 minutes in) it's also covered in the transcript "In patients with pain, there’s a change in kidney function. When the pain is worse, they have lost a lot of amino acids and electrolytes through the urine.".

    He also issues a health warning "This is preliminary data. Clearly, this data may still be nothing. But we have to make sure that this makes sense, and that it’s not “no-sense”.
     
    pattismith likes this.
  4. jaybee00

    jaybee00

    Messages:
    80
    Likes:
    94
    @Marky90

    or whomever

    Did they suggest anything to treat this decrease in flow mediated dilation? The arginine/citrulline mixture?
     
  5. Marky90

    Marky90 Science breeds knowledge, opinion breeds ignorance

    Messages:
    1,218
    Likes:
    4,541
    Cant treat an unknown cause..
     
  6. msf

    msf Senior Member

    Messages:
    3,197
    Likes:
    4,484
  7. IThinkImTurningJapanese

    IThinkImTurningJapanese Moderator

    Messages:
    849
    Likes:
    1,755
    Japan
    pattismith likes this.
  8. FMMM1

    FMMM1

    Messages:
    91
    Likes:
    147
    Did a little plagiarism myself; although this is likely from Fluge and Mella themselves: “Fluge and Mella are pursuing autoantibodies in their Rituximab work, and autoantibodies appear to play major role in some cases of postural orthostatic intolerance syndrome (POTS)” [from another webpage - dated October 7, 2017]. So perhaps this subgroup have causal/contributing autoantibodies.

    Haven't read your comments or those of others, but just maybe this will help to understand some cases.

    Was the "p-001 decreases in flow mediated dilation" a positive response to Rituximab and if so what % of patients responded?

    I guess "pilot patients" are participants in previous studies.

    Sorry if you've already explained this in previous posts.
     
    Learner1 and Gingergrrl like this.
  9. Gingergrrl

    Gingergrrl Senior Member

    Messages:
    9,532
    Likes:
    24,617
    USA
    @FMMM1 I was curious where your quote came from re: Fluge & Mella from 10/7/17? I am thrilled (from the quote) if they are pursuing autoantibodies in their Rituximab work and the role that they play in some cases in autoimmune POTS b/c this is exactly MY situation! I would love to read more about this. Thank you in advance!
     
    pattismith likes this.
  10. Murph

    Murph :)

    Messages:
    520
    Likes:
    2,670
    I used a special database exploitattion algorithm I know of and am able to confirm the quote comes from Simarron research, i.e. Cort.
     
  11. Gingergrrl

    Gingergrrl Senior Member

    Messages:
    9,532
    Likes:
    24,617
    USA
    My utter lack of computer skills is unclear if you are joking about the "special database exploitattion algorithm" or if this is a quote from Fluge & Mella that was reported on by Cort? How would I find the original if it is out there? :D
     
  12. IThinkImTurningJapanese

    IThinkImTurningJapanese Moderator

    Messages:
    849
    Likes:
    1,755
    Japan
    Gingergrrl likes this.
  13. FMMM1

    FMMM1

    Messages:
    91
    Likes:
    147
    Yea but I'm a little worried in case the quote comes from an earlier conversation i.e. before the study was unblinded (September 2017). However, if "p-001 decreases in flow mediated dilation" is a positive response to Rituximab then this quote could provide a possible answer i.e. "autoantibodies appear to play major role in some cases of postural orthostatic intolerance syndrome (POTS)”.

    Hopefully, I haven't falsely raised peoples hopes.
     
    Jesse2233 and Gingergrrl like this.
  14. Learner1

    Learner1 Professional Patient

    Messages:
    1,192
    Likes:
    1,968
    Pacific Northwest
    That is what I was understanding and my hope for Rituximab treatment.

    Even with the failure of the trial, it seems that it does help a few patients. Which subset would benefit and why?

    Or are there other B cell strategies (like bortezomib) which may be more effective for certain patients? And what are the risks?

    The devil is in the details, and it doest seem like there a "one size fits all" solution.
     
  15. andyguitar

    andyguitar Senior Member

    Messages:
    264
    Likes:
    373
    South east England
    Somewhere in the dim and distant past there was a reference to CFS being called "T Cell disease" This was years ago. Anyone heard it called that?
     
  16. jaybee00

    jaybee00

    Messages:
    80
    Likes:
    94
    So could use clarification if the difference in flow mediated dilation referred to differences between the control and the treatment group at 24 months in the phase III study or if this is referring to differences between PWCFS in this study versus non-CFS controls...
     
  17. Gingergrrl

    Gingergrrl Senior Member

    Messages:
    9,532
    Likes:
    24,617
    USA
    @FMMM1 What does "decreases in flow mediated dilation" as a study measurement with Rituximab mean vs. the mechanism of Ritux killing the B cells? Thanks!
     
  18. FMMM1

    FMMM1

    Messages:
    91
    Likes:
    147
    Reverting to plagiarism (again)!

    I came across this elsewhere on the web "Fluge and Mella believe ME/CFS may be an autoimmune disorder that attacks the blood vessels".

    Treatment with Rituximab resulted in better regulation of blood flow in some of those who were treated (%?). I.e. increased blood flow resulted in increased widening of blood vessels (dilation) in these patients.

    Treatment with Rituximab wipes out your B-cells. B-cells produce antibodies, including autoimmune antibodies. Therefore, better regulation of blood flow following treatment with Rituximab suggests that some people with ME/CFS may have "an autoimmune disorder that attacks the blood vessels".

    I suggest that we are cautious (not necessarily how I am all of the time) and wait to see the paper i.e. have the views of those (Fluge and Mella) who have a better understanding.
     
    Ruthie24, hinterland and Gingergrrl like this.
  19. FMMM1

    FMMM1

    Messages:
    91
    Likes:
    147
    Google "community symposium on the molecular basis of me/cfs mark davis" and select the YouTube video. It's about 18 minutes long; check out 15.30 minutes [it shows activated T-cells in ME/CFS, Lyme and MS] and 16.40 minutes [summarises findings].

    Plagiarism again "The working hypothesis at Stanford University is that ME is an autoimmune disease" [from "Follow ME in Denmark" - check out the article re Mark Davis's presentation].
     
    Ruthie24 likes this.
  20. Learner1

    Learner1 Professional Patient

    Messages:
    1,192
    Likes:
    1,968
    Pacific Northwest
    Today, I'm going to an Immune Deficiency Foundation conference in my city. In digging around in their website, I found this video from their conference earlier this year.

    Its a very easy to understand tutorial on the immune system and how autoimmunity can develop in people with immune system defects. Starting at around1:00 he discusses treatment, including high dose IVIG, Rituximab, Bortizimub, and plasmapherisis.



    For a subset of patients, it looks like from this angle, Rituximab might work. But likely not everyone here on PR fits this profile. And, as he says, there are risks involved.
     
    Ruthie24, pibee and Gingergrrl like this.

See more popular forum discussions.

Share This Page